Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels

Trial Profile

Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Plerixafor (Primary) ; Bortezomib
  • Indications Stem cell mobilisation
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top